Other Nutri-Pharm Products
SPX9
SPX9 is a novel topical antimicrobial technology based on the above principles. It is a topical ointment with antibacterial, antifungal, anti-inflammatory and wound healing properties. SPX9 contains a broad range of components with well known antimicrobial activity, and is novel in its antimicrobial scope, design and efficacy. SPX9 is the ninth iteration and refinement of the project, optimising antimicrobial properties, stability, safety, and ease of use.
SPX9 Test Stock
| Microbial Species | SPX9 cfu reduction |
|---|---|
| Ecoli | 99.67% |
| Candida Albicans | 99.67% |
| Pseudomonas Aeruginosa | 99.77% |
| MRSA (Methicillin Resistant Staphylococcus Aureus) | 99.84% |
| Carbapenem Resistant K. pneumoniae | 99.92% |
| Acinetobacter Baumannii | 99.94% |
| Clostridium Sporogenes | 94.81% |
This testing represents five of the six most dangerous species listed in the Lancet article.
SPX Alpha
SPX Alpha is an aqueous based topical technology, established on the multiple antimicrobial components, multiple mechanisms of action philosophy of SPX9. SPX Alpha is designed for use in wounds, particularly those infected with AMR pathogens. SPX Alpha is currently in development. Specific compounds with documented activity against AMR pathogenic species have been used in the formulation. Other selected characteristics are anti-inflammatory and wound healing properties.
Nanocellulose Product
Nanocellulose is derived from wood fibre and has been shown to retain active antimicrobial molecules extremely efficiently. Research conducted by us demonstrated that nanocellulose retained functional components to a degree of 1150% greater than standard cellulose.
Status: A highly promising technology for many commercial applications. Nutri-Pharm is seeking partnerships for the development of this novel antimicrobial product.
Polymers
Nutri-Pharm antimicrobial technologies include specialised application to polymers. A study conducted with treated polymer water containers showed decreased biofilm related mass compared with control samples, with a total net biofilm related weight loss of 650mg compared with control samples. This constituted a reduction in biofilm associated weight of 39.9% with the treated polymers.
The development of polymer products which possess intrinsic or surface expressed antimicrobial properties is of great value in many applications. Nutri-Pharm is undertaking further research in this area and welcomes industry partnerships.